Johannes Waltenberger

Tumor necrosis factor- (cid:1) plays an important role in restenosis development

A. Zwinderman, R. J. Winter, J. Jukema, 2005 .

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

H. Huikuri, H. Suryapranata, A. Bagai, 2024, European heart journal. Cardiovascular pharmacotherapy.

A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions: study design and protocol.

A. Kastrati, A. Colombo, J. Waltenberger, 2010 .